Literature DB >> 23902153

Serologic and molecular investigations of DAR1 (weak D Type 4.2), DAR1.2, DAR1.3, DAR2 (DARE), and DARA.

Sofia Lejon Crottet1, Lonneke Haer-Wigman, Peter Gowland, Stefano Fontana, Christoph Niederhauser, Hein Hustinx.   

Abstract

BACKGROUND: The partial D variant DAR1 (weak D Type 4.2) is caused by three single-point mutations, 602C>G, 667T>G, and 1025T>C. Here we report a molecular study on different D variants belonging to the DAR category (DAR1, DAR1.2, DAR1.3, and DAR2) and their serologic data. STUDY DESIGN AND METHODS: A total of 42 samples belonging to the DAR category were screened for the presence of the silent mutations 744C>T and 957G>A. The samples were phenotyped for RhD and RhCE, characterized for RhD epitope expression, and sequenced for RHD exons. Flow cytometry was performed to determine RhD antigen density.
RESULTS: The silent mutation 744C>T was found in all six samples previously typed as RHD*DAR2 (602C>G, 667T>G, 957G>A, 1025T>C). In addition to the three nucleotide changes originally reported for the RHD*DAR1 allele, the silent mutations 744C>T and 957G>A were found in 14 of 16 samples previously typed as RHD*DAR1. In the remaining two samples one additional silent mutation, 744C>T, was found. Serologically the DAR1.2 and DAR1.3 samples analyzed in this study showed no distinct difference in their anti-D reaction pattern compared to each other. The anti-D reaction pattern of DARA/DAR2 showed some distinct differences compared to those of DAR1.2 and DAR1.3.
CONCLUSION: RHD*DARA and RHD*DAR2 are the same allele. Furthermore, the alleles RHD*DAR1.2 and RHD*DAR1.3 both exist; however, the silent mutation 957G>A (V319) showed no influence on the RhD phenotype.
© 2013 American Association of Blood Banks.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23902153     DOI: 10.1111/trf.12363

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  2 in total

1.  RHD Genotyping of Rh-Negative and Weak D Phenotype among Blood Donors in Southeast Iran.

Authors:  Younes Sadeghi-Bojd; Naser Amirizadeh; Arezoo Oodi
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2021-10-01

2.  Impact on patient of the detection of weakly expressed RhD antigens in blood donors.

Authors:  Helio Moraes-Souza; Vitor Mendonça Alves
Journal:  Rev Bras Hematol Hemoter       Date:  2015-08-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.